HC Wainwright reissued their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $60.00 price target on the stock.
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an overweight rating on shares of Belite Bio in a report on Thursday, June 20th. Benchmark reaffirmed a buy rating and set a $57.00 target price on shares of Belite Bio in a research note on Tuesday, August 13th.
Check Out Our Latest Report on Belite Bio
Belite Bio Stock Up 0.2 %
Belite Bio (NASDAQ:BLTE – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Equities analysts expect that Belite Bio will post -1.19 earnings per share for the current fiscal year.
Institutional Trading of Belite Bio
An institutional investor recently bought a new position in Belite Bio stock. Jump Financial LLC bought a new stake in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,200 shares of the company’s stock, valued at approximately $238,000. 0.53% of the stock is currently owned by hedge funds and other institutional investors.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Featured Articles
- Five stocks we like better than Belite Bio
- What Investors Need to Know to Beat the Market
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is an Earnings Surprise?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.